179 related articles for article (PubMed ID: 15886503)
1. Is there an indication for high-dose chemotherapy in the treatment of bone and soft-tissue sarcoma?
Kasper B; Ho AD; Egerer G
Oncology; 2005; 68(2-3):115-21. PubMed ID: 15886503
[TBL] [Abstract][Full Text] [Related]
2. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
3. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Toma S; Palumbo R; Canavese G; Albanese E; Cantoni E; Barisone A; Reggiardo G; Rosso R; Santi L
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S222-7. PubMed ID: 8453703
[TBL] [Abstract][Full Text] [Related]
4. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
5. High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
Demetri GD
Semin Oncol; 1996 Jun; 23(3 Suppl 6):22-6. PubMed ID: 8677444
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
7. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
8. The role of high-dose therapy and autologous stem cell transplantation for pediatric bone and soft tissue sarcomas.
Ek ET; Choong PF
Expert Rev Anticancer Ther; 2006 Feb; 6(2):225-37. PubMed ID: 16445375
[TBL] [Abstract][Full Text] [Related]
9. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
10. High-dose chemotherapy in adult sarcomas: no standard yet.
Seynaeve C; Verweij J
Semin Oncol; 1999 Feb; 26(1):119-33. PubMed ID: 10073568
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensive chemotherapy in advanced adult soft tissue sarcoma.
Verma S; Bramwell V
Expert Rev Anticancer Ther; 2002 Apr; 2(2):201-15. PubMed ID: 12113242
[TBL] [Abstract][Full Text] [Related]
12. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
14. High-dose therapy for adult soft tissue sarcoma: dose response and survival.
Elias AD
Semin Oncol; 1998 Apr; 25(2 Suppl 4):19-23; discussion 45-8. PubMed ID: 9578058
[TBL] [Abstract][Full Text] [Related]
15. A role for maintenance therapy in managing sarcoma.
Ray-Coquard I; Le Cesne A
Cancer Treat Rev; 2012 Aug; 38(5):368-78. PubMed ID: 21843915
[TBL] [Abstract][Full Text] [Related]
16. Dose-intensive chemotherapy with stem cell support as a treatment strategy for bone and soft-tissue sarcomas.
Kasper B; Ho AD; Egerer G
Curr Stem Cell Res Ther; 2006 Jan; 1(1):29-35. PubMed ID: 18220851
[TBL] [Abstract][Full Text] [Related]
17. [Soft tissue sarcoma: postoperative chemotherapy].
Goto T; Kosaku H; Kobayashi H; Hozumi T; Kondo T
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1324-30. PubMed ID: 15446551
[TBL] [Abstract][Full Text] [Related]
18. [Chemotherapy for pulmonary metastases of soft tissue sarcoma].
Kito M; Umeda T
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1701-6. PubMed ID: 9757195
[TBL] [Abstract][Full Text] [Related]
19. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
